OP-1 trial under way:
This article was originally published in Clinica
Executive Summary
Stryker (US) has completed patient recruitment in its OP-1 fracture healing trial. Creative BioMolecules, developer of the OP-1 morphogenic protein, says most patients have already been treated. An undisclosed number of patients will be followed for nine months to see whether OP-1 performs better than bone chips in non-union fractures.